Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 70HER2-positive Breast Cancer 15Carcinoma, Non-Small-Cell Lung 6HER2 Positive Metastatic Breast Cancer 4Breast Diseases 4Brain Neoplasms 4HER2 Positive Breast Cancer 3Advanced Breast Cancer 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Salivary Gland Neoplasms 2HER2-positive Metastatic Breast Cancer 2Colorectal Neoplasms 2Breast Cancer Invasive 2Breast Cancer Female 2Solid Tumor 1Rare Tumour 1Rare Tumor 1Pathologic Complete Response 1Non-squamous NSCLC 1Non Small Cell Lung 1Neoplasm Metastasis 1Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer 1Metastatic Breast Cancer in the Brain 1Lung Neoplasms 1Locally Advanced Breast Cancer 1HER2-positive Early Breast Cancer 1HER2-positive Advanced Breast Cancer 1HER2-expressing Advanced Solid Tumors 1HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane 1

Interventions

Fulvestrant 6Letrozole 4Capecitabine 4exemestane 3dalpiciclib 3Trastuzumab 3Docetaxel 3Anastrozole 3ribociclib 2palbociclib 2fluzoparib 2apatinib 2Irinotecan 2Gemcitabine 2tusamitamab ravtansine 1trastuzumab deruxtecan 1sacituzumab govitecan 1pyrotinib 1pegfilgrastim 1patritumab deruxtecan 1olaparib 1nirogacestat 1margetuximab 1irinotecan sucrosofate 1abemaciclib 1Zoledronic Acid 1Vinorelbine 1Tamoxifen 1Rogaratinib 1Patient Reported Outcome Measures 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Cancer Metastatic × pyrotinib × Clear all
NCT06718933 2025-02-06

Study of SHR-A1811 Combined With Pyrotinib and Bevacizumab in Advanced Breast Cancer With Brain Metastasis

Fudan University

Phase 1/2 Recruiting
74 enrolled
Breast

Breast Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡